Table 2 Characteristics of included articles
| Â | N = 77 (%) |
|---|---|
Name of journal | |
 - NEJM | 3 (4) |
 - The Lancet | 2 (3) |
 - JAMA | 13 (17) |
 - Annals of Internal Medicine | 9 (11) |
 - BMJ | 14 (18) |
 - PLoS Medicine | 8 (11) |
 - Circulation | 7 (9) |
 - European Heart Journal | 4 (5) |
 - Journal of the American College of Cardiology | 15 (19) |
Location of corresponding authors | |
 - North America | 40 (52) |
 - Europe | 25 (32) |
 - Asia | 10 (13) |
 - North American and Europe | 1 (1) |
 - International | 1 (1) |
Study design | |
 - Cohort study | 67 (87) |
 - Not clearly reported | 10 (13) |
Treatment evaluated | |
 - Pharmacological treatment | 53 (69) |
 - Non-pharmacological treatment | 23 (30) |
 - Both | 1 (1) |
Comparator | |
 - Active comparator | 49 (63) |
 - Usual care | 17 (22) |
 - No treatment | 11 (14) |
Median sample size [min–max] | 24,000 [9100–80,000] |
Data sourcea | |
 - Registry | 34 (44) |
 - Electronic health record | 17 (22) |
 - Health administration data | 14 (18) |
 - Health insurance claims data | 20 (26) |
 - Others | 11 (14) |
Funding source | |
 - Not for profit | 43 (56) |
 - For profit | 7 (9) |
 - Both | 12 (16) |
 - No funding | 5 (6) |
 - Unclear | 10 (13) |
Research transparency practices | |
 - Using a reporting guideline | 7 (9) |
 - Code and algorithm used to classify exposures provided in supplementary documents | 57 (74) |
 - Code and algorithm used to classify outcomes provided in supplementary documents | 60 (78) |
 - A statement to provide data upon request | 10 (13) |